Skip to main content

Table 3 Association of HDAC1 expression with various clinicopathological factors

From: Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

Characteristic

All cases

HDAC 1 low (IRS 0–4)

HDAC 1 intermediate (IRS 6–8)

HDAC 1 high (IRS 9–12)

P-valueχ 2-test for trends

All cases

208 (100%)

71 (34.1%)

69 (33.2%)

68 (32.7%)

--

Histological type

    

0.17

Ductal carcinoma/Other

176 (100%)

62 (35.2%)

60 (34.1%)

54 (30.7%)

 

Lobular carcinoma

28 (100%)

7 (25%)

9 (32.1%)

12 (42.9%)

 

Histological grade

    

0.89

G1

61 (100%)

24 (39.3%)

20 (32.8%)

17 (27.9%)

 

G2

90 (100%)

25 (27.8%)

28 (31.1%)

37 (41.1%)

 

G3

53 (100%)

20 (37.8%)

21 (39.6%)

12 (22.6%)

 

Nodal status

    

0.23

negative

129 (100%)

48 (37.2%)

42 (32.6%)

39 (30.2%)

 

positive

67 (100%)

18 (26.9%)

26 (38.8%)

23 (34.3%)

 

pT-Stage

    

0.88

pT1

116 (100%)

41 (35.3%)

37 (31.9%)

38 (32.8%)

 

pT2/pT3

78 (100%)

23 (29.5%)

30 (38.5%)

25 (32%)

 

pT4

9 (100%)

4 (44.4%)

2 (22.2%)

3 (33.4%)

 

Hormone receptor status

    

<0.001*

Hormone receptor positive

162 (100%)

46 (28.4%)

54 (33.3%)

62 (38.3%)

 

Hormone receptor negative

41 (100%)

22 (53.7%)

15 (36.6%)

4 (9.7%)

 

HER2 status

    

0.71

negative

175 (100%)

60 (34.3%)

58 (33.1%)

57 (32.6%)

 

positive

25 (100%)

9 (36%)

9 (36%)

7 (28%)